Cargando…
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
BACKGROUND: In this study, we examined patients who had non-progressive disease for at least 2 years after diagnosis of inoperable locoregional recurrent or metastatic breast cancer under continuous trastuzumab treatment. Our primary goal was to assess the long-term outcome of patients with durable...
Autores principales: | Witzel, Isabell, Müller, Volkmar, Abenhardt, Wolfgang, Kaufmann, Manfred, Schoenegg, Winfried, Schneeweis, Andreas, Jänicke, Fritz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230522/ https://www.ncbi.nlm.nih.gov/pubmed/25371387 http://dx.doi.org/10.1186/1471-2407-14-806 |
Ejemplares similares
-
Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014) -
Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021) -
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
por: Müller, Volkmar, et al.
Publicado: (2018) -
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012) -
Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2014)